Trial record 1 of 1 for:    E1412
Previous Study | Return to List | Next Study

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

This study is currently recruiting participants.
Verified January 2014 by National Cancer Institute (NCI)
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01856192
First received: May 14, 2013
Last updated: April 7, 2014
Last verified: January 2014
  Purpose

This randomized phase II trial studies how well rituximab and combination chemotherapy with or without lenalidomide works in treating patients with newly diagnosed stage II-IV diffuse large B cell lymphoma. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. It is not yet known whether rituximab and combination chemotherapy are more effective when given with or without lenalidomide in treating patients with diffuse large B cell lymphoma.


Condition Intervention Phase
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma
Stage IV Adult Diffuse Large Cell Lymphoma
Drug: lenalidomide
Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Other: laboratory biomarker analysis
Procedure: positron emission tomography
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • PFS [ Time Frame: Time from randomization to the earliest of documented disease progression, new primaries of the same type or death without progression, assessed up to 10 years ] [ Designated as safety issue: No ]
    The primary analysis of PFS will be performed including all randomized eligible patients using a one-sided log-rank test stratified on IPI (2-3 vs. 4-5), age (< 60 years vs >= 60 years) and molecular subtype (germinal center B-cell type [GCB] vs. activated B-cell type [ABC]). Cox proportional hazards models will be used to assess possible effects of baseline clinical and biological characteristics on outcome, including age, gender, disease stage, and IPI. Treatment and covariate interactions will also be examined.


Secondary Outcome Measures:
  • Overall RR based on PET-CT scan [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
    The comparison of RR between two arms will be performed with Cochran-Mantel-Haenszel (CMH) test, stratified on IPI (2-3 vs 4-5), age (< 60 yrs vs >= 60 yrs) and molecular subtype (GCB vs. ABC). Exploratory logistic regression will be used to assess possible effects of baseline clinical and biological characteristics on outcome, including age, gender, disease stage, and IPI. Treatment and covariate interactions will also be examined.

  • CR rate based on PET-CT scan [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
    The comparison of CR between two arms will be performed with CMH test, stratified on IPI (2-3 vs 4-5), age (< 60 yrs vs >= 60 yrs) and molecular subtype (GCB vs. ABC). Exploratory logistic regression will be used to assess possible effects of baseline clinical and biological characteristics on outcome, including age, gender, disease stage, and IPI. Treatment and covariate interactions will also be examined.

  • OS [ Time Frame: Time from randomization until death due to any cause, assessed up to 10 years ] [ Designated as safety issue: No ]
    The method of Kaplan and Meier will be used to estimate OS, and stratified log-rank test will be used to compare OS between two arms.


Other Outcome Measures:
  • Impact of DLBCL molecular subtype on outcome [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
  • Relation between interim PET scan and study outcome [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: August 2013
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A (rituximab, combination chemotherapy, lenalidomide)
Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, prednisone PO on days 1-5, and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Drug: lenalidomide
Given PO
Other Names:
  • CC-5013
  • IMiD-1
  • Revlimid
Biological: rituximab
Given IV
Other Names:
  • IDEC-C2B8
  • IDEC-C2B8 monoclonal antibody
  • Mabthera
  • MOAB IDEC-C2B8
  • Rituxan
Drug: cyclophosphamide
Given IV
Other Names:
  • CPM
  • CTX
  • Cytoxan
  • Endoxan
  • Endoxana
Drug: doxorubicin hydrochloride
Given IV
Other Names:
  • ADM
  • ADR
  • Adria
  • Adriamycin PFS
  • Adriamycin RDF
Drug: vincristine sulfate
Given IV
Other Names:
  • leurocristine sulfate
  • VCR
  • Vincasar PFS
Drug: prednisone
Given PO
Other Names:
  • DeCortin
  • Deltra
Other: laboratory biomarker analysis
Correlative studies
Procedure: positron emission tomography
Correlative studies
Other Names:
  • FDG-PET
  • PET
  • PET scan
  • tomography, emission computed
Active Comparator: Arm B (rituximab, combination chemotherapy)
Patients receive rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone as in Arm A. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Biological: rituximab
Given IV
Other Names:
  • IDEC-C2B8
  • IDEC-C2B8 monoclonal antibody
  • Mabthera
  • MOAB IDEC-C2B8
  • Rituxan
Drug: cyclophosphamide
Given IV
Other Names:
  • CPM
  • CTX
  • Cytoxan
  • Endoxan
  • Endoxana
Drug: doxorubicin hydrochloride
Given IV
Other Names:
  • ADM
  • ADR
  • Adria
  • Adriamycin PFS
  • Adriamycin RDF
Drug: vincristine sulfate
Given IV
Other Names:
  • leurocristine sulfate
  • VCR
  • Vincasar PFS
Drug: prednisone
Given PO
Other Names:
  • DeCortin
  • Deltra
Other: laboratory biomarker analysis
Correlative studies
Procedure: positron emission tomography
Correlative studies
Other Names:
  • FDG-PET
  • PET
  • PET scan
  • tomography, emission computed

Detailed Description:

PRIMARY OBJECTIVES:

I. Progression-free survival (PFS).

SECONDARY OBJECTIVES:

I. Response rate (RR). II. Complete remission (CR) rate as defined by positron emission tomography (PET)-computed tomography (CT) criteria.

III. Overall survival (OS).

TERTIARY OBJECTIVES:

I. Impact of diffuse large B cell lymphoma (DLBCL) molecular subtype on outcome.

II. Interim PET scan results in relation to treatment outcome.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM A: Patients receive rituximab intravenously (IV), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, prednisone orally (PO) on days 1-5, and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone as in Arm A. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patient are followed up every 3 months for 2 years, every 6 months for 1 year and then annually for up to 7 years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed DLBCL expressing cluster of differentiation (CD)20 antigen (Journal of Clinical Oncology [J Clin Oncol] 17[4]:1244-53, 1999); patients with known primary mediastinal large B-cell lymphoma (PMLBCL) are excluded; similarly, patients with known v-myc myelocytomatosis viral oncogene homolog (avian) (c-myc) translocation (by fluorescence in situ hybridization) positive DLBCL are encouraged to participate in trials specifically designed for these patients; however patients with known c-myc positive are NOT excluded from this study; c-myc testing prior to study enrollment is NOT required
  • Stages II bulky disease (defined as mass size of more than 10 cm), stage III, or IV (Ann Arbor Staging); patients with stage I and stage II non-bulky disease are excluded from this study
  • A tumor tissue specimen from the initial diagnostic biopsy has been located and ready to ship to the Eastern Cooperative Oncology Group (ECOG) Pathology Coordinating Office within 30 days following registration; patients must have paraffin-embedded tumor specimen available for central pathology review and defined laboratory research studies; archived formalin fixed paraffin embedded (FFPE) tumor tissue block is required; if the block is unavailable for submission, please submit the below alternative requirements:

    • One (1) hematoxylin & eosin (H&E) slide, and
    • Twenty (20) 4 um unstained air-dried plus slides, and
    • One (1) or more core punches (minimum of 4 mm diameter)
  • International Prognostic Index (IPI) of 2 or greater
  • ECOG performance status 0-2
  • Patients must have measurable disease (at least 1 lesion of >= 1.5 cm in one diameter) as detected by CT or the CT images of the PET/CT
  • Previously untreated and not receiving any other agent that would be considered as a treatment for the lymphoma
  • No known central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells; these patients are usually treated with CNS directed therapy; screening for cerebrospinal fluid (CSF)/CNS involvement is NOT required but can be performed per treating medical doctor (MD) discretion
  • Absolute neutrophil count (ANC) >= 1500
  • Platelets (PLT) >= 100,000
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) or if total bilirubin is > 1.5 x ULN, the direct bilirubin must be normal
  • Alkaline (Alk.) phosphatase =< 3 x ULN unless evidence of the direct liver involvement by lymphoma--then =< 5 x ULN
  • Aspartate aminotransferase (AST) =< 3 x ULN unless evidence of the direct liver involvement by lymphoma-then =< 5 x ULN
  • Creatinine =< 2 x ULN or creatinine clearance (CrCl) > 30 ml/min
  • Ejection fraction of >= 45% by either multi gated acquisition scan (MUGA) or echocardiogram (ECHO)
  • Absence of co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Absence of history of myocardial infarction =< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
  • Absence of history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia; patients with history of deep vein thrombosis/embolism/thrombophilia may participate if they are on full anticoagulation during the treatment (warfarin or low molecular weight heparin at therapeutic doses)
  • Patient must be able and willing to receive anticoagulation therapy with aspirin 325 mg daily prophylaxis, low molecular weight heparin, or warfarin; patients unable or unwilling to take any prophylaxis are NOT eligible
  • Absence of history of acquired immune deficiency syndrome (AIDS)-related conditions (other than the presenting DLBCL) or posttransplant lymphoproliferative disorder (PTLD) in immunocompromised patients; patients with human immunodeficiency virus (HIV) on antiretroviral therapy other than zidovudine (AZT) and/or stavudine and without prior AIDS defining conditions and adequate CD4 count (> 400) are eligible
  • No another active malignancy requiring therapy such as radiation, chemotherapy, or immunotherapy; exceptions to this are as follows: localized nonmelanotic skin cancer and any cancer that in the judgment of the investigator has been treated with curative intent and will not interfere with the study treatment plan and response assessment
  • No history of radiation therapy to >= 25% of the bone marrow for other diseases or history of anthracycline therapy
  • Patients must not be receiving erythroid stimulating agents (erythropoietin [EPO]: Procrit, Aranesp)
  • Patient must be willing to provide informed written consent and to return to enrolling institution for follow-up
  • Women must not be pregnant or breast-feeding
  • Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide; FCBP must also agree to ongoing pregnancy testing; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy; all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01856192

  Hide Study Locations
Locations
United States, Arizona
Mayo Clinic in Arizona Recruiting
Scottsdale, Arizona, United States, 85259
Contact: Grzegorz S. Nowakowski    507-538-7623      
Principal Investigator: Grzegorz S. Nowakowski         
United States, Colorado
The Medical Center of Aurora Recruiting
Aurora, Colorado, United States, 80012
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Boulder Community Hospital Recruiting
Boulder, Colorado, United States, 80301
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Penrose-Saint Francis Healthcare Recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Colorado Cancer Research Program CCOP Recruiting
Denver, Colorado, United States, 80224-2522
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Presbyterian - Saint Lukes Medical Center - Health One Recruiting
Denver, Colorado, United States, 80218
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rose Medical Center Recruiting
Denver, Colorado, United States, 80220
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Exempla Saint Joseph Hospital Recruiting
Denver, Colorado, United States, 80218
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Rose Recruiting
Denver, Colorado, United States, 80220
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Midtown Recruiting
Denver, Colorado, United States, 80218
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Colorado Blood Cancer Institute Recruiting
Denver, Colorado, United States, 80907
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Porter Adventist Hospital Recruiting
Denver, Colorado, United States, 80210
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Mercy Medical Center Recruiting
Durango, Colorado, United States, 81301
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Swedish Medical Center Recruiting
Englewood, Colorado, United States, 80113
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Comprehensive Cancer Care and Research Institute of Colorado LLC Recruiting
Englewood, Colorado, United States, 80113
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Mountain Blue Cancer Care Center Recruiting
Golden, Colorado, United States, 80401
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
North Colorado Medical Center Recruiting
Greeley, Colorado, United States, 80631
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Breast Cancer Care Consultants Recruiting
Greenwood Village, Colorado, United States, 80111
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Lakewood Recruiting
Lakewood, Colorado, United States, 80228
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Saint Anthony Hospital Recruiting
Lakewood, Colorado, United States, 80228
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Littleton Adventist Hospital Recruiting
Littleton, Colorado, United States, 80122
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Sky Ridge Recruiting
Lone Tree, Colorado, United States, 80124
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Sky Ridge Medical Center Recruiting
Lone Tree, Colorado, United States, 80124
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Longmont United Hospital Recruiting
Longmont, Colorado, United States, 80501
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
McKee Medical Center Recruiting
Loveland, Colorado, United States, 80539
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Parker Recruiting
Parker, Colorado, United States, 80138
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Parker Adventist Hospital Recruiting
Parker, Colorado, United States, 80138
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Saint Mary Corwin Medical Center Recruiting
Pueblo, Colorado, United States, 81004
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Exempla Lutheran Medical Center Recruiting
Wheat Ridge, Colorado, United States, 80033
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
United States, Connecticut
Saint Francis Hospital and Medical Center Recruiting
Hartford, Connecticut, United States, 06105
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
The Hospital of Central Connecticut Recruiting
New Britain, Connecticut, United States, 06050
Contact: Brian J. Byrne    860-224-5660      
Principal Investigator: Brian J. Byrne         
United States, Delaware
Beebe Medical Center Recruiting
Lewes, Delaware, United States, 19958
Contact: Gregory A. Masters    302-733-6227      
Principal Investigator: Gregory A. Masters         
Christiana Care Health System-Christiana Hospital Recruiting
Newark, Delaware, United States, 19718
Contact: Gregory A. Masters    302-733-6227      
Principal Investigator: Gregory A. Masters         
United States, Georgia
Emory University/Winship Cancer Institute Recruiting
Atlanta, Georgia, United States, 30322
Contact: Jonathon B. Cohen    404-778-1868      
Principal Investigator: Jonathon B. Cohen         
United States, Idaho
Saint Alphonsus Regional Medical Center Recruiting
Boise, Idaho, United States, 83706
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
United States, Illinois
Illinois CancerCare-Bloomington Recruiting
Bloomington, Illinois, United States, 61701
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Canton Recruiting
Canton, Illinois, United States, 61520
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Carthage Recruiting
Carthage, Illinois, United States, 62321
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Adam M. Petrich    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Adam M. Petrich         
Decatur Memorial Hospital Recruiting
Decatur, Illinois, United States, 62526
Contact: James L. Wade    217-876-4740    kcheek@dmhhs.org   
Principal Investigator: James L. Wade         
Illinois CancerCare-Eureka Recruiting
Eureka, Illinois, United States, 61530
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Galesburg Cottage Plaza Office Recruiting
Galesburg, Illinois, United States, 61401
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Hinsdale Hematology Oncology Associates Incorporated Recruiting
Hinsdale, Illinois, United States, 60521
Contact: Elyse Schneiderman    630-654-1790    info@hhoaltd.com   
Principal Investigator: Elyse Schneiderman         
Illinois CancerCare-Kewanee Clinic Recruiting
Kewanee, Illinois, United States, 61443
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Macomb Recruiting
Macomb, Illinois, United States, 61455
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Trinity Medical Center Recruiting
Moline, Illinois, United States, 61265
Contact: David M. Spector    309-779-4200      
Principal Investigator: David M. Spector         
Illinois CancerCare-Monmouth Recruiting
Monmouth, Illinois, United States, 61462
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Ottawa Clinic Recruiting
Ottawa, Illinois, United States, 61350
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Pekin Recruiting
Pekin, Illinois, United States, 61603
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois Oncology Research Association CCOP Recruiting
Peoria, Illinois, United States, 61615
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Peoria Recruiting
Peoria, Illinois, United States, 61615
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Peru Recruiting
Peru, Illinois, United States, 61354
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Princeton Recruiting
Princeton, Illinois, United States, 61356
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
SwedishAmerican Regional Cancer Center/ACT Recruiting
Rockford, Illinois, United States, 61107
Contact: Harvey E. Einhorn    779-696-9400    cancercare@swedishamerican.org   
Principal Investigator: Harvey E. Einhorn         
Swedish American Hospital Withdrawn
Rockford, Illinois, United States, 61104
Memorial Medical Center Recruiting
Springfield, Illinois, United States, 62781-0001
Contact: James L. Wade    217-876-4740    kcheek@dmhhs.org   
Principal Investigator: James L. Wade         
United States, Indiana
Indiana University Medical Center Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Michael J. Robertson    317-274-2552      
Principal Investigator: Michael J. Robertson         
United States, Iowa
McFarland Clinic PC-William R Bliss Cancer Center Recruiting
Ames, Iowa, United States, 50010
Contact: Joseph J. Merchant    515-239-2621      
Principal Investigator: Joseph J. Merchant         
Mercy Medical Center - North Iowa Recruiting
Mason City, Iowa, United States, 50401
Contact: Arvind Y. Vemula    800-433-3883      
Principal Investigator: Arvind Y. Vemula         
Ottumwa Regional Health Center Recruiting
Ottumwa, Iowa, United States, 52501
Contact: Praveen Vikas    641-684-2742      
Principal Investigator: Praveen Vikas         
Siouxland Hematology Oncology Associates Recruiting
Sioux City, Iowa, United States, 51101
Contact: Donald B. Wender    712-252-0088      
Principal Investigator: Donald B. Wender         
United States, Kansas
Lawrence Memorial Hospital Recruiting
Lawrence, Kansas, United States, 66044
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Wesley Medical Center Recruiting
Wichita, Kansas, United States, 67214
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
United States, Louisiana
Ochsner Health Center-Summa Recruiting
Baton Rouge, Louisiana, United States, 70809
Contact: Robert V. Emmons    888-562-4763      
Principal Investigator: Robert V. Emmons         
Ochsner Medical Center Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Robert V. Emmons    888-562-4763      
Principal Investigator: Robert V. Emmons         
United States, Maryland
Greater Baltimore Medical Center Recruiting
Baltimore, Maryland, United States, 21204
Contact: Gary I. Cohen    443-849-3706      
Principal Investigator: Gary I. Cohen         
United States, Massachusetts
Tufts Medical Center Recruiting
Boston, Massachusetts, United States, 02111
Contact: Andrew M. Evens    617-636-5000    ContactUsCancerCenter@TuftsMedicalCenter.org   
Principal Investigator: Andrew M. Evens         
University of Massachusetts Medical School Recruiting
Worcester, Massachusetts, United States, 01655
Contact: Alan G. Rosmarin    508-856-3216    cancer.research@umassmed.edu   
Principal Investigator: Alan G. Rosmarin         
United States, Michigan
Saint Joseph Mercy Hospital Recruiting
Ann Arbor, Michigan, United States, 48106-0995
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Saint John Hospital and Medical Center Recruiting
Detroit, Michigan, United States, 48236
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Green Bay Oncology - Escanaba Recruiting
Escanaba, Michigan, United States, 49431
Contact: Gerald K. Bayer    800-432-6049      
Principal Investigator: Gerald K. Bayer         
Green Bay Oncology - Iron Mountain Recruiting
Iron Mountain, Michigan, United States, 49801
Contact: Gerald K. Bayer    800-432-6049      
Principal Investigator: Gerald K. Bayer         
West Michigan Cancer Center Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Raymond S. Lord    269-373-7458      
Principal Investigator: Raymond S. Lord         
Saint Joseph Mercy Port Huron Recruiting
Port Huron, Michigan, United States, 48060
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Saint John Macomb-Oakland Hospital Recruiting
Warren, Michigan, United States, 48093
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
United States, Minnesota
Sanford Clinic North-Bemidgi Recruiting
Bemidji, Minnesota, United States, 56601
Contact: Preston D. Steen    701-234-6161      
Principal Investigator: Preston D. Steen         
Fairview Ridges Hospital Recruiting
Burnsville, Minnesota, United States, 55337
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Mercy Hospital Recruiting
Coon Rapids, Minnesota, United States, 55433
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Fairview-Southdale Hospital Recruiting
Edina, Minnesota, United States, 55435
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Unity Hospital Recruiting
Fridley, Minnesota, United States, 55432
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Hutchinson Area Health Care Recruiting
Hutchinson, Minnesota, United States, 55350
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Minnesota Oncology Hematology PA-Maplewood Recruiting
Maplewood, Minnesota, United States, 55109
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Saint John's Hospital - Healtheast Recruiting
Maplewood, Minnesota, United States, 55109
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Abbott-Northwestern Hospital Recruiting
Minneapolis, Minnesota, United States, 55407
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Hennepin County Medical Center Recruiting
Minneapolis, Minnesota, United States, 55415
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
North Memorial Medical Health Center Recruiting
Robbinsdale, Minnesota, United States, 55422
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Grzegorz S. Nowakowski    507-538-7623      
Principal Investigator: Grzegorz S. Nowakowski         
Park Nicollet Clinic - Saint Louis Park Recruiting
Saint Louis Park, Minnesota, United States, 55416
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Metro-Minnesota CCOP Recruiting
Saint Louis Park, Minnesota, United States, 55416
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Regions Hospital Recruiting
Saint Paul, Minnesota, United States, 55101
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
United Hospital Recruiting
Saint Paul, Minnesota, United States, 55102
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Saint Francis Regional Medical Center Recruiting
Shakopee, Minnesota, United States, 55379
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Lakeview Hospital Recruiting
Stillwater, Minnesota, United States, 55082
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Ridgeview Medical Center Recruiting
Waconia, Minnesota, United States, 55387
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Rice Memorial Hospital Recruiting
Willmar, Minnesota, United States, 56201
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
Minnesota Oncology and Hematology PA-Woodbury Recruiting
Woodbury, Minnesota, United States, 55125
Contact: Joseph W. Leach    952-993-1517    MMCCOP@parknicollet.com   
Principal Investigator: Joseph W. Leach         
United States, Missouri
Saint Francis Medical Center Recruiting
Cape Girardeau, Missouri, United States, 63703
Contact: James L. Wade    217-876-4740    kcheek@dmhhs.org   
Principal Investigator: James L. Wade         
United States, Nebraska
Nebraska Cancer Research Center Recruiting
Lincoln, Nebraska, United States, 68510
Contact: Gamini S. Soori    800-253-4368      
Principal Investigator: Gamini S. Soori         
United States, Nevada
Nevada Cancer Research Foundation CCOP Recruiting
Las Vegas, Nevada, United States, 89106
Contact: John A. Ellerton    702-384-0013      
Principal Investigator: John A. Ellerton         
United States, New Hampshire
New Hampshire Oncology-Hematology PA Recruiting
Concord, New Hampshire, United States, 03301
Contact: Frederick M. Briccetti    800-339-6484      
Principal Investigator: Frederick M. Briccetti         
New Hampshire Oncology Hematology Associates Recruiting
Hooksett, New Hampshire, United States, 03106
Contact: Frederick M. Briccetti    800-339-6484      
Principal Investigator: Frederick M. Briccetti         
LRGHealthcare-Lakes Region General Hospital Recruiting
Laconia, New Hampshire, United States, 03246
Contact: Frederick M. Briccetti    800-339-6484      
Principal Investigator: Frederick M. Briccetti         
United States, New Jersey
Cooper Hospital University Medical Center Recruiting
Camden, New Jersey, United States, 08103
Contact: Gregory A. Masters    302-733-6227      
Principal Investigator: Gregory A. Masters         
Inspira Medical Center Vineland Recruiting
Vineland, New Jersey, United States, 08360
Contact: Ramakrishna R. Sudhindra    856-641-7933      
Principal Investigator: Ramakrishna R. Sudhindra         
United States, New York
Albert Einstein College of Medicine Recruiting
Bronx, New York, United States, 10461
Contact: Ramakrishna Battini    718-904-2730    aecc@aecom.yu.edu   
Principal Investigator: Ramakrishna Battini         
Montefiore Medical Center Recruiting
Bronx, New York, United States, 10467-2490
Contact: Ramakrishna Battini    718-904-2730    aecc@aecom.yu.edu   
Principal Investigator: Ramakrishna Battini         
New York University Langone Medical Center Recruiting
New York, New York, United States, 10016
Contact: Catherine S. Diefenbach    212-263-4434    prmc.coordinator@nyumc.org   
Principal Investigator: Catherine S. Diefenbach         
United States, North Dakota
Sanford Bismarck Medical Center Recruiting
Bismarck, North Dakota, United States, 58501
Contact: Preston D. Steen    701-234-6161      
Principal Investigator: Preston D. Steen         
Roger Maris Cancer Center Recruiting
Fargo, North Dakota, United States, 58122
Contact: Preston D. Steen    701-234-6161      
Principal Investigator: Preston D. Steen         
Sanford Clinic North-Fargo Recruiting
Fargo, North Dakota, United States, 58122
Contact: Preston D. Steen    701-234-6161      
Principal Investigator: Preston D. Steen         
Sanford Medical Center-Fargo Recruiting
Fargo, North Dakota, United States, 58122
Contact: Preston D. Steen    701-234-6161      
Principal Investigator: Preston D. Steen         
United States, Ohio
Summa Akron City Hospital/Cooper Cancer Center Recruiting
Akron, Ohio, United States, 44304
Contact: Jennifer E. Payne    330-375-6101      
Principal Investigator: Jennifer E. Payne         
Summa Barberton Hospital Recruiting
Barberton, Ohio, United States, 44203
Contact: Jennifer E. Payne    330-375-6101      
Principal Investigator: Jennifer E. Payne         
Mercy Medical Center Recruiting
Canton, Ohio, United States, 44708
Contact: Mitchell Haut    888-293-4673      
Principal Investigator: Mitchell Haut         
Case Western Reserve University Recruiting
Cleveland, Ohio, United States, 44106
Contact: Paolo F. Caimi    800-641-2422      
Principal Investigator: Paolo F. Caimi         
Columbus CCOP Recruiting
Columbus, Ohio, United States, 43215
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
The Mark H Zangmeister Center Recruiting
Columbus, Ohio, United States, 43219
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Mount Carmel Health Center West Recruiting
Columbus, Ohio, United States, 43222
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
Riverside Methodist Hospital Recruiting
Columbus, Ohio, United States, 43214
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
Marietta Memorial Hospital Recruiting
Marietta, Ohio, United States, 45750
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
Licking Memorial Hospital Recruiting
Newark, Ohio, United States, 43055
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Springfield Regional Medical Center Recruiting
Springfield, Ohio, United States, 45505
Contact: John P. Kuebler    614-566-3275      
Principal Investigator: John P. Kuebler         
Flower Hospital Recruiting
Sylvania, Ohio, United States, 43560
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
University of Toledo Recruiting
Toledo, Ohio, United States, 43614
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
Saint Ann's Hospital Recruiting
Westerville, Ohio, United States, 43081
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
United States, Pennsylvania
Saint Luke's University Hospital-Bethlehem Campus Recruiting
Bethlehem, Pennsylvania, United States, 18015
Contact: Neil D. Belman    610-954-3582    infolink@slhn.org   
Principal Investigator: Neil D. Belman         
Bryn Mawr Hospital Recruiting
Bryn Mawr, Pennsylvania, United States, 19010
Contact: Albert S. DeNittis    866-225-5654      
Principal Investigator: Albert S. DeNittis         
Geisinger Medical Center Recruiting
Danville, Pennsylvania, United States, 17822-2001
Contact: Edward J. Gorak    570-271-5251      
Principal Investigator: Edward J. Gorak         
Delaware County Memorial Hospital Recruiting
Drexel Hill, Pennsylvania, United States, 19026
Contact: Michael M. Mikhail    610-284-8237    jolene.garney@crozer.org   
Principal Investigator: Michael M. Mikhail         
Adams Cancer Center Recruiting
Gettysburg, Pennsylvania, United States, 17325
Contact: Amir Tabatabai    877-441-7957      
Principal Investigator: Amir Tabatabai         
Cherry Tree Cancer Center Recruiting
Hanover, Pennsylvania, United States, 17331
Contact: Amir Tabatabai    877-441-7957      
Principal Investigator: Amir Tabatabai         
Geisinger Medical Center-Cancer Center Hazelton Recruiting
Hazleton, Pennsylvania, United States, 18201
Contact: Edward J. Gorak    570-271-5251      
Principal Investigator: Edward J. Gorak         
Penn State Milton S Hershey Medical Center Recruiting
Hershey, Pennsylvania, United States, 17033-0850
Contact: Witold B. Rybka    717-531-3779    CTO@hmc.psu.edu   
Principal Investigator: Witold B. Rybka         
Paoli Memorial Hospital Recruiting
Paoli, Pennsylvania, United States, 19301
Contact: Albert S. DeNittis    866-225-5654      
Principal Investigator: Albert S. DeNittis         
Thomas Jefferson University Hospital Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Barbara Pro    215-955-6084      
Principal Investigator: Barbara Pro         
Fox Chase Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contact: Nadia Khan    215-728-4790      
Principal Investigator: Nadia Khan         
Grand View Hospital Recruiting
Sellersville, Pennsylvania, United States, 18960
Contact: Anthony J. Magdalinski    215-453-4162    PParsons@gvh.org   
Principal Investigator: Anthony J. Magdalinski         
Mount Nittany Medical Center Recruiting
State College, Pennsylvania, United States, 16803
Contact: Witold B. Rybka    717-531-3779    CTO@hmc.psu.edu   
Principal Investigator: Witold B. Rybka         
Reading Hospital Recruiting
West Reading, Pennsylvania, United States, 19611
Contact: Terrence P. Cescon    610-988-9323      
Principal Investigator: Terrence P. Cescon         
Geisinger Wyoming Valley Recruiting
Wilkes-Barre, Pennsylvania, United States, 18711
Contact: Edward J. Gorak    570-271-5251      
Principal Investigator: Edward J. Gorak         
Lankenau Hospital Recruiting
Wynnewood, Pennsylvania, United States, 19096
Contact: Albert S. DeNittis    866-225-5654      
Principal Investigator: Albert S. DeNittis         
WellSpan Health-York Hospital Recruiting
York, Pennsylvania, United States, 17405
Contact: Amir Tabatabai    877-441-7957      
Principal Investigator: Amir Tabatabai         
United States, South Dakota
Sanford Cancer Center-Oncology Clinic Recruiting
Sioux Falls, South Dakota, United States, 57104
Contact: Miroslaw A. Mazurczak    605-328-1367      
Principal Investigator: Miroslaw A. Mazurczak         
Sanford USD Medical Center - Sioux Falls Recruiting
Sioux Falls, South Dakota, United States, 57117-5134
Contact: Miroslaw A. Mazurczak    605-328-1367      
Principal Investigator: Miroslaw A. Mazurczak         
United States, Tennessee
Vanderbilt-Ingram Cancer Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Nishitha Reddy    800-811-8480      
Principal Investigator: Nishitha Reddy         
United States, Texas
University Medical Center Brackenridge Recruiting
Austin, Texas, United States, 78701
Contact: Alka Mallik    512-324-7991      
Principal Investigator: Alka Mallik         
University of Texas Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Contact: Harris V. Naina    214-648-7097      
Principal Investigator: Harris V. Naina         
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Michael E. Williams    434-243-6143      
Principal Investigator: Michael E. Williams         
United States, Wisconsin
Sacred Heart Hospital Recruiting
Eau Claire, Wisconsin, United States, 54701
Contact: Ali W. Bseiso    715-389-4457      
Principal Investigator: Ali W. Bseiso         
Marshfield Clinic Cancer Center at Sacred Heart Recruiting
Eau Claire, Wisconsin, United States, 54701
Contact: Ali W. Bseiso    715-389-4457      
Principal Investigator: Ali W. Bseiso         
Green Bay Oncology Limited at Saint Mary's Hospital Recruiting
Green Bay, Wisconsin, United States, 54303
Contact: Gerald K. Bayer    800-432-6049      
Principal Investigator: Gerald K. Bayer         
Green Bay Oncology at Saint Vincent Hospital Recruiting
Green Bay, Wisconsin, United States, 54301-3526
Contact: Gerald K. Bayer    800-432-6049      
Principal Investigator: Gerald K. Bayer         
Saint Vincent Hospital Recruiting
Green Bay, Wisconsin, United States, 54301
Contact: Gerald K. Bayer    800-432-6049      
Principal Investigator: Gerald K. Bayer         
Saint Mary's Hospital Recruiting
Green Bay, Wisconsin, United States, 54303
Contact: Gerald K. Bayer    800-432-6049      
Principal Investigator: Gerald K. Bayer         
Aurora BayCare Medical Center Recruiting
Green Bay, Wisconsin, United States, 54311-6519
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Gundersen Lutheran Recruiting
La Crosse, Wisconsin, United States, 54601
Contact: Kurt Oettel    608-775-2385    cancerctr@gundluth.org   
Principal Investigator: Kurt Oettel         
Dean Hematology and Oncology Clinic Recruiting
Madison, Wisconsin, United States, 53717
Contact: Amit Sanyal    608-410-2700      
Principal Investigator: Amit Sanyal         
Vince Lombardi Cancer Clinic-Marinette Recruiting
Marinette, Wisconsin, United States, 54143
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Marshfield Clinic Recruiting
Marshfield, Wisconsin, United States, 54449
Contact: Ali W. Bseiso    715-389-4457      
Principal Investigator: Ali W. Bseiso         
Saint Joseph's Hospital Recruiting
Marshfield, Wisconsin, United States, 54449
Contact: Ali W. Bseiso    715-389-4457      
Principal Investigator: Ali W. Bseiso         
Froedtert and the Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Timothy S. Fenske    414-805-4380      
Principal Investigator: Timothy S. Fenske         
Marshfield Clinic-Minocqua Center Recruiting
Minocqua, Wisconsin, United States, 54548
Contact: Ali W. Bseiso    715-389-4457      
Principal Investigator: Ali W. Bseiso         
Oconomowoc Memorial Hospital-ProHealth Care Inc Recruiting
Oconomowoc, Wisconsin, United States, 53066-3896
Contact: Timothy R. Wassenaar    262-928-7878      
Principal Investigator: Timothy R. Wassenaar         
Green Bay Oncology - Oconto Falls Recruiting
Oconto Falls, Wisconsin, United States, 54154
Contact: Gerald K. Bayer    800-432-6049      
Principal Investigator: Gerald K. Bayer         
Marshfield Clinic at James Beck Cancer Center Recruiting
Rhinelander, Wisconsin, United States, 54501
Contact: Ali W. Bseiso    715-389-4457      
Principal Investigator: Ali W. Bseiso         
Saint Mary's Hospital Recruiting
Rhinelander, Wisconsin, United States, 54501
Contact: Ali W. Bseiso    715-389-4457      
Principal Investigator: Ali W. Bseiso         
Marshfield Clinic-Rice Lake Center Recruiting
Rice Lake, Wisconsin, United States, 54868
Contact: Ali W. Bseiso    715-389-4457      
Principal Investigator: Ali W. Bseiso         
Saint Michael's Hospital Recruiting
Stevens Point, Wisconsin, United States, 54481
Contact: Ali W. Bseiso    715-389-4457      
Principal Investigator: Ali W. Bseiso         
Marshfield Clinic Cancer Care at Saint Michael's Hospital Recruiting
Stevens Point, Wisconsin, United States, 54481
Contact: Ali W. Bseiso    715-389-4457      
Principal Investigator: Ali W. Bseiso         
Green Bay Oncology - Sturgeon Bay Recruiting
Sturgeon Bay, Wisconsin, United States, 54235
Contact: Gerald K. Bayer    800-432-6049      
Principal Investigator: Gerald K. Bayer         
Aurora Medical Center in Summit Recruiting
Summit, Wisconsin, United States, 53066
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Waukesha Memorial Hospital - ProHealth Care Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Timothy R. Wassenaar    262-928-7878      
Principal Investigator: Timothy R. Wassenaar         
Marshfield Clinic-Wausau Center Recruiting
Wausau, Wisconsin, United States, 54401
Contact: Ali W. Bseiso    715-389-4457      
Principal Investigator: Ali W. Bseiso         
Aspirus Regional Cancer Center Recruiting
Wausau, Wisconsin, United States, 54401
Contact: Hamied R. Rezazadeh    877-405-6866      
Principal Investigator: Hamied R. Rezazadeh         
Aurora Cancer Care-Milwaukee West Recruiting
Wauwatosa, Wisconsin, United States, 53226
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Marshfield Clinic - Weston Center Recruiting
Weston, Wisconsin, United States, 54476
Contact: Ali W. Bseiso    715-389-4457      
Principal Investigator: Ali W. Bseiso         
Marshfield Clinic - Wisconsin Rapids Center Recruiting
Wisconsin Rapids, Wisconsin, United States, 54494
Contact: Ali W. Bseiso    715-389-4457      
Principal Investigator: Ali W. Bseiso         
Sponsors and Collaborators
Investigators
Principal Investigator: Grzegorz Nowakowski Eastern Cooperative Oncology Group
  More Information

No publications provided

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01856192     History of Changes
Other Study ID Numbers: NCI-2013-00959, NCI-2013-00959, ECOG-E1412, E1412, E1412, U10CA021115
Study First Received: May 14, 2013
Last Updated: April 7, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Monoclonal
Cyclophosphamide
Rituximab
Thalidomide
Lenalidomide
Doxorubicin
Prednisone
Vincristine
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Immunosuppressive Agents
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antibiotics, Antineoplastic

ClinicalTrials.gov processed this record on April 17, 2014